Today, finalized a national coverage decision for FDA-approved CAR T therapies that treat certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia.
While today’s announcement ensures consistent coverage of CAR-T cell therapy, last Friday CMS announced changes to Medicare’s payment policies for CAR-T and other innovative therapies, to ensure appropriate payment for new technologies.
#Medicare will cover CAR-T cell therapies for FDA-approved indications (according to the FDA-approved label) & for off-label uses that are recommended by CMS-approved compendia.
. will leverage information obtained from the -FDA’s required post-approval safety studies for CAR-T cell therapies to the fullest extent possible, as it’s important to monitor responses to the therapies in the #Medicare population.